This week, the top managed care news included a panel mostly endorsed the use of patient-reported outcomes for coverage of chimeric antigen receptor T-cell therapy; the US Preventive Services Task Force released new recommendations for cervical cancer screening; research found accountable care organization penetration may be changing how physicians work.
A panel examines how CMS should pay for chimeric antigen receptor (CAR) T-cell therapy, women receive new recommendations for cervical cancer screening, and a study shows accountable care organizations (ACOs) may be changing how doctors work.
Welcome to This Week in Managed Care, I’m Laura Joszt.
Use of PROs for CAR T
A CMS panel held a daylong hearing to discuss a national coverage determination for CAR T cell therapy, the game-changing cancer treatment approved by FDA for two indications and being studied for more.
CMS’ Medicare Evidence Development and Coverage Advisory Committee, known as MEDCAC, looked at evidence on patient-reported outcomes as it relates to CAR T.
UnitedHealthcare, a large manager of Medicare Advantage plans, asked CMS to start the process because of concerns over the cost of these individualized gene therapies, which can cost more than $400,000 and are difficult to administer.
Peter Bach, MD, of Memorial Sloan Kettering Cancer Center noted in the New England Journal of Medicine ahead of the meeting that despite the promise of CAR T cell therapy, these treatments are not without risk.
Screening for Cervical Cancer
How often women should be screened for cervical cancer depends on their age and other factors, according to new recommendations from the US Preventive Services Task Force.
Changes published this week give women ages 30 to 65 new options:
Women ages 21 to 30 should receive a Pap test every 3 years.
While testing has led to a decline in deaths from cervical cancer, 4170 women will die from the disease this year, according to the American Cancer Society.
Impact of ACOs on Physician Hours
Growth of accountable care organizations, or ACOs, may be changing physician working patterns, and this may be helping doctors to work fewer hours.
A new study in JAMA Network Open suggests that as the number of ACOs increased, physicians were less likely to be self-employed, but they also worked fewer hours.
The data show:
The authors concluded: “Given the wave of concern over physician burnout, it will be important to assess job satisfaction among physicians in ACOs to understand whether ACOs might help to alleviate some of the concerns currently besetting physicians.”
Saving Money in Medicare
Lower-cost generic drugs could save Medicare more than $900 million a year, according to researchers from Harvard Medical School and Brigham and Women’s hospital.
The study in JAMA calculated the difference between what Medicare spent on brand-name combinations and what would have been spent if those drugs were swapped for their generic components.
Role of Diabetes Educators
Robert Gabbay, MD, PhD, FACP, chief medical officer at Joslin Diabetes Center, told members of the American Association of Diabetes Educators last week that they can play a critical role in the transition to value-based care.
“We’ve long been in the fee-for-service world, where the incentive is to do things. We’re moving to one where value is key," he said.
Gabbay said educators help people with diabetes avoid complications and hospital stays, and this will be rewarded with new incentive structures.
Read more coverage of the AADE annual meeting.
Cancer Survivorship
As cancer survivors live longer, the medical system must address challenges with late effects, being lost to follow-up, and financial hardship.
The current issue of Evidence-Based Oncology looks at survivorship, led by a cover story from Florida Cancer Specialists’ Lucio Gordan, MD, and Don Champlain.
For all of us at the Managed Markets News Network, I’m Laura Joszt. Thanks for joining us.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More